Project Grant R01HL188641
Award Date 8/15/26
Completion Date 5/31/30
Dollars Obligated $820K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $149,214 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lipid-loaded macrophages in atherosclerotic plaque inflammation. The recipient will characterize the metabolic landscape and cell fate decisions of atheroma-derived macrophages under lipid loading, examining how lipid-associated macrophages release extracellular adenosine triphosphate as a pro-inflammatory signaling...
- The National Institutes of Health National Heart, Lung and Blood Institute awarded Boston Children's Hospital $1,628,604 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct molecular research on atherosclerosis regulation, with performance through June 30, 2028. The project investigates endothelial dysfunction and chronic inflammation as critical regulators of plaque destabilization in atherosclerosis, focusing on the role of CD47 as a cell-surface...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $593,663 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate thrombolysis resistance in acute ischemic stroke with large vessel occlusion. The project addresses the failure of intravenous thrombolysis with tissue plasminogen activator (TPA) to achieve successful recanalization in most eligible patients. Mayo Clinic will conduct three integrated research activities: define metabolic...
- The National Heart, Lung, and Blood Institute awarded Wake Forest University Health Sciences $2.402 million on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to map the molecular and cellular conversion of normal human coronary artery tissue to atherosclerotic plaque and identify therapeutic targeting opportunities for atherosclerotic vascular disease. The recipient will leverage its existing tissue biorepository of human coronary and aortic samples from trauma...
- The National Heart Lung and Blood Institute awarded Icahn School of Medicine at Mount Sinai $763,862 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the metabolic control of immune cell function in atherogenesis. The research examines the role of methylmalonic acid (MMA)—a byproduct of propionyl-CoA catabolism—in macrophage inflammatory processes that drive atherosclerotic cardiovascular disease. Preliminary data show that genetic deficiency of...
- The National Heart, Lung, and Blood Institute awarded New York University $763,960 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms by which long non-coding RNA IRF1-AS1 and its mouse ortholog GM12216 regulate atherosclerotic cardiovascular disease. The research will examine how IRF1-AS1 coordinates expression of protein-coding genes including the transcriptional regulator IRF1 in myeloid cells to drive atherogenesis,...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $773,466 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 3, 2026, to investigate CXCL5-CXCR2 signaling mechanisms in macrophage cholesterol efflux and atherosclerosis prevention. The research integrates systems biology, pharmacology, and atherosclerosis expertise across three aims: elucidating CXCL5-CXCR2 signaling mechanisms using multi-omics and CRISPR-Cas9 in human...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic Arizona $1,665,204 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how P2RX7-expressing CD4+ T cells control virus-induced lung sequelae. The research defines how severe respiratory infections such as influenza and SARS-CoV-2 promote pathogenic lung CD4+ T cell accumulation that perpetuates long-term lung damage, including the irreversible organ dysfunction observed in long COVID...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic Arizona $249,000 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the pathogenic mechanisms of platelet factor 4 (PF4)–reactive antibodies in antibody-mediated thrombotic disorders including heparin-induced thrombocytopenia, vaccine-induced immune thrombotic thrombocytopenia, and monoclonal gammopathy of thrombotic significance. The project, titled "Determinants of...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,500 on March 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage biology in atherosclerosis and atherosclerosis-related cardiometabolic disease. The award funds a comprehensive program exploring the role of macrophage efferocytosis and resolution cycles in promoting fibrous cap thickening in atherosclerotic plaques and...